Last fall, the Alliance convened a ground-breaking meeting in Washington, DC, to consider some of the most challenging topics facing the ovarian cancer community. A group of researchers, oncologists, regulatory experts, advocates and industry representatives attempted to answer questions such as: “How can more women be treated where they live?” “How can we facilitate increased awareness and use of patient reported outcomes?” and “What can we expect from personalized medicine in the next few years?”
Our experts’ opinions and recommendations on patient reported outcomes, access to clinical trials at the community level and personalized medicine have been summarized in a white paper and published in an editorial in the journal Gynecologic Oncology.
Download a PDF of our white paper.
Read the editorial in Gynecologic Oncology [subscription required].
